Literature DB >> 33047688

Discharge against medical advice from a Mission tertiary hospital, South-West, Nigeria.

Y T Olasinde1, M A Alao1, E Agelebe1.   

Abstract

BACKROUND: The fiduciary duty of a managing physician makes paediatric discharges against medical advice (DAMA) particularly challenging as children lack the legal power or authority to make their health decisions. Aim: It is aimed in the present study to determine the prevalence of paediatric DAMA in a mission tertiary hospital.
METHODS: This was a prospective descriptive study carried out from June 2018 to May 2019 among paediatric inpatients at the Bowen University Teaching Hospital, Ogbomoso, Nigeria whose parent/ care giver signed DAMA, despite adequate counselling. Data was analysed using SPSS version 23.
RESULTS: The prevalence of DAMA in the study was of 4.1%, and the neonatal group accounted for the largest bulk of DAMA. Birth asphyxia was the commonest diagnosis among this group. There was a slight female predominance among the patients whose parents signed DAMA. Financial constraint was the commonest reason [13(30.2%)] given for DAMA and none of the children whose parents signed DAMA was enrolled on the National Health Insurance Scheme (NHIS).
CONCLUSION: Rate of DAMA in a private mission tertiary hospital was lower than previously reported from government tertiary hospitals in the present-day Nigeria.

Entities:  

Keywords:  Discharge against medical advice; Mission hospital; pediatrics; tertiary

Mesh:

Year:  2020        PMID: 33047688     DOI: 10.4103/njcp.njcp_118_20

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  1 in total

1.  Effectiveness of Faith-Based Interventions on the Rate of Discharged Against Medical Advice in Tertiary Newborn Units in Nigeria: A Protocol for an Open Label Randomized Control Trial.

Authors:  Michael Abel Alao; Olayinka Rasheed Ibrahim; Babatunde Oluwatosin Ogunbosi; Emmanuel Okechukwu Nna; Peter Olamakinde Olapegba
Journal:  Front Public Health       Date:  2022-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.